Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.

PloS one - 1 Jan 2020

Graham Laura S, Montgomery Bruce, Cheng Heather H, Yu Evan Y, Nelson Peter S, Pritchard Colin, Erickson Stephanie, Alva Ajjai, Schweizer Michael T

Abstract excerpt

BACKGROUND: While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite instability (MSI) are thought likely to respond favorably. To date, there is limited published data on this biologically distinct and clinically relevant subgroup's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Neoplasm Metastasis

Share to Neoplastic Syndromes, Hereditary

Share to Programmed Cell Death 1 Receptor

Share to Prostatic Neoplasms

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32453797
DOI: 10.1371/journal.pone.0233260
PMCID: PMC7250457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.PMID 32453797Read ↗

Clinical Implications of Mismatch Repair Deficiency in Prostate CancerSemantic proximity Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patientsSemantic proximity Read ↗

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read ↗

Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.Semantic proximity Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.Semantic proximity Read ↗

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.Semantic proximity Read ↗

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.Semantic proximity Read ↗

Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.